Roche licenses Zymeworks’ trispecific T cell engager targeting DLL3
Zymeworks has entered into a global license and collaboration agreement with Roche for the research, development and commercialisation of ZW209, a T cell engager targeting DLL3. Under the agreement, Zymeworks is eligible to receive an upfront payment of $55 million, a $40 million payment upon initiation of… Read More
